Product portfolio

Biotie's first product is already on the market and we have a broad pipeline of novel, potentially first or best-in class products in clinical development.

Our focus is on generating innovative, clinically differentiated medicines for the treatment of neurodegenerative and psychiatric diseases based on strong scientific, medical and commercial rationale. We aim to advance our products through Phase 2 before seeking a partnership with large pharma or biotech for late stage development and commercialization. In situations where we believe we can be competitive, e.g. for specialty or orphan indications, we will progress our pipeline internally to registration, approval and market. We have a dedicated team of scientists, in Europe and the US, with the drive and enthusiasm to deliver new medicines to patients.

Portfolio of Innovative CNS Medicines

Development Product Candidates

Portfolio

Tozadenant

Indication

Parkinson's Disease

Phase 1

Phase 2

Phase 3

Marketed

Status

Phase 3 trial top-line efficacy data expected by YE-2017

Portfolio

SYN120

Indication

Parkinson's Disease Dementia

Phase 1

Phase 2

Phase 3

Marketed

Status

Phase 2a trial top-line data expected in the second half of 2017

Portfolio

SYN120

Indication

Alzheimer's Disease

Phase 1

Phase 2

Phase 3

Marketed

Status

Phase 2 trial ready (funding dependent)

Portfolio

BTT1023

Indication

Primary Sclerosing Cholangitis

Phase 1

Phase 2

Phase 3

Marketed

Status

Phase 2a trial interim data expected in the first half of 2017

Commercial Product

Portfolio

Selincro

Indication

Alcohol Dependence

Phase 1

Phase 2

Phase 3

Marketed

Status

Launched across Europe by our partner Lundbeck

Updated 10 August, 2016